Dr. Cohen will discuss the Company's growth strategy focused on the development of novel drugs that engage the immune system to treat rare, life-threatening diseases with unmet medical need. He will also provide an update on the progress of Corbus' three clinical programs for Resunab™, a first-in-class, synthetic oral drug intended to resolve chronic inflammation and halt fibrosis. Resunab is currently being evaluated in Phase 2 clinical studies for cystic fibrosis, diffuse cutaneous systemic sclerosis, and skin-predominant dermatomyositis. Top-line safety and efficacy data from these Phase 2 studies is expected to be reported starting at the end of 2016.